ABSTRACT
DAB486IL-2 is a novel fusion toxin in which the ADP-ribosyltransferase and membrane-translocating domains of diphtheria toxin have been combined with the interleukin-2 (IL-2) gene, creating a recombinant protein capable of selectively intoxicating cells bearing the high-affinity IL-2 receptor. Clinical activity has been documented in Hodgkin disease and the non-Hodgkin lymphomas; toxicities have been minimal and include mild hepatic transaminitis, proteinuria, and hypersensitivity reactions. In this report, a patient with tumor-stage cutaneous T-cell lymphoma developed clinical adrenal failure with bilateral adrenal hemorrhage and necrosis 7 weeks after completing a 5-day course of treatment with DAB486IL-2. The relationship of fusion toxin therapy to the development of this unusual toxicity is discussed.
Subject(s)
Adrenal Gland Diseases/etiology , Diphtheria Toxin/adverse effects , Diphtheria Toxin/pharmacology , Hemorrhage/etiology , Immunotoxins/adverse effects , Interleukin-2/adverse effects , Interleukin-2/pharmacology , Adrenal Gland Diseases/pathology , Adrenal Gland Neoplasms/pathology , Adrenal Gland Neoplasms/therapy , Adrenal Insufficiency/etiology , Aged , Hemorrhage/pathology , Humans , Immunotoxins/therapeutic use , Lymphoma, T-Cell, Cutaneous/pathology , Lymphoma, T-Cell, Cutaneous/therapy , Male , Necrosis/etiology , Neoplasm Invasiveness , Recombinant Fusion Proteins/adverse effects , Recombinant Fusion Proteins/therapeutic useABSTRACT
The echoencephalographic examinations of 127 neonates were analysed to verify the role of US in the study of neonatal cerebral pathology, and to compare it with CT. US was of value in identifying the existence of a cerebral lesion and for follow-up. CT was more reliable for the characterization of the lesion and in establishing the surgical indications.
